Cargando…
The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study
INTRODUCTION: Pulmonary arterial hypertension (PAH) is a major cause of mortality in systemic sclerosis (SSc). Screening guidelines for PAH recommend multiple investigations, including annual echocardiography, which together have low specificity and may not be cost-effective. We sought to evaluate t...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978999/ https://www.ncbi.nlm.nih.gov/pubmed/24246100 http://dx.doi.org/10.1186/ar4383 |
_version_ | 1782310667591614464 |
---|---|
author | Thakkar, Vivek Stevens, Wendy Prior, David Youssef, Peter Liew, Danny Gabbay, Eli Roddy, Janet Walker, Jennifer G Zochling, Jane Sahhar, Joanne Nash, Peter Lester, Susan Rischmueller, Maureen Proudman, Susanna M Nikpour, Mandana |
author_facet | Thakkar, Vivek Stevens, Wendy Prior, David Youssef, Peter Liew, Danny Gabbay, Eli Roddy, Janet Walker, Jennifer G Zochling, Jane Sahhar, Joanne Nash, Peter Lester, Susan Rischmueller, Maureen Proudman, Susanna M Nikpour, Mandana |
author_sort | Thakkar, Vivek |
collection | PubMed |
description | INTRODUCTION: Pulmonary arterial hypertension (PAH) is a major cause of mortality in systemic sclerosis (SSc). Screening guidelines for PAH recommend multiple investigations, including annual echocardiography, which together have low specificity and may not be cost-effective. We sought to evaluate the predictive accuracy of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) in combination with pulmonary function tests (PFT) (‘proposed’ algorithm) in a screening algorithm for SSc-PAH. METHODS: We evaluated our proposed algorithm (PFT with NT-proBNP) on 49 consecutive SSc patients with suspected pulmonary hypertension undergoing right heart catherisation (RHC). The predictive accuracy of the proposed algorithm was compared with existing screening recommendations, and is presented as sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). RESULTS: Overall, 27 patients were found to have pulmonary hypertension (PH) at RHC, while 22 had no PH. The sensitivity, specificity, PPV and NPV of the proposed algorithm for PAH was 94.1%, 54.5%, 61.5% and 92.3%, respectively; current European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines achieved a sensitivity, specificity, PPV and NPV of 94.1%, 31.8%, 51.6% and 87.5%, respectively. In an alternate case scenario analysis, estimating a PAH prevalence of 10%, the proposed algorithm achieved a sensitivity, specificity, PPV and NPV for PAH of 94.1%, 54.5%, 18.7% and 98.8%, respectively. CONCLUSIONS: The combination of NT-proBNP with PFT is a sensitive, yet simple and non-invasive, screening strategy for SSc-PAH. Patients with a positive screening result can be referred for echocardiography, and further confirmatory testing for PAH. In this way, it may be possible to shift the burden of routine screening away from echocardiography. The findings of this study should be confirmed in larger studies. |
format | Online Article Text |
id | pubmed-3978999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-39789992014-04-09 The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study Thakkar, Vivek Stevens, Wendy Prior, David Youssef, Peter Liew, Danny Gabbay, Eli Roddy, Janet Walker, Jennifer G Zochling, Jane Sahhar, Joanne Nash, Peter Lester, Susan Rischmueller, Maureen Proudman, Susanna M Nikpour, Mandana Arthritis Res Ther Research Article INTRODUCTION: Pulmonary arterial hypertension (PAH) is a major cause of mortality in systemic sclerosis (SSc). Screening guidelines for PAH recommend multiple investigations, including annual echocardiography, which together have low specificity and may not be cost-effective. We sought to evaluate the predictive accuracy of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) in combination with pulmonary function tests (PFT) (‘proposed’ algorithm) in a screening algorithm for SSc-PAH. METHODS: We evaluated our proposed algorithm (PFT with NT-proBNP) on 49 consecutive SSc patients with suspected pulmonary hypertension undergoing right heart catherisation (RHC). The predictive accuracy of the proposed algorithm was compared with existing screening recommendations, and is presented as sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). RESULTS: Overall, 27 patients were found to have pulmonary hypertension (PH) at RHC, while 22 had no PH. The sensitivity, specificity, PPV and NPV of the proposed algorithm for PAH was 94.1%, 54.5%, 61.5% and 92.3%, respectively; current European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines achieved a sensitivity, specificity, PPV and NPV of 94.1%, 31.8%, 51.6% and 87.5%, respectively. In an alternate case scenario analysis, estimating a PAH prevalence of 10%, the proposed algorithm achieved a sensitivity, specificity, PPV and NPV for PAH of 94.1%, 54.5%, 18.7% and 98.8%, respectively. CONCLUSIONS: The combination of NT-proBNP with PFT is a sensitive, yet simple and non-invasive, screening strategy for SSc-PAH. Patients with a positive screening result can be referred for echocardiography, and further confirmatory testing for PAH. In this way, it may be possible to shift the burden of routine screening away from echocardiography. The findings of this study should be confirmed in larger studies. BioMed Central 2013 2013-11-19 /pmc/articles/PMC3978999/ /pubmed/24246100 http://dx.doi.org/10.1186/ar4383 Text en Copyright © 2013 Thakkar et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Thakkar, Vivek Stevens, Wendy Prior, David Youssef, Peter Liew, Danny Gabbay, Eli Roddy, Janet Walker, Jennifer G Zochling, Jane Sahhar, Joanne Nash, Peter Lester, Susan Rischmueller, Maureen Proudman, Susanna M Nikpour, Mandana The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study |
title | The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study |
title_full | The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study |
title_fullStr | The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study |
title_full_unstemmed | The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study |
title_short | The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study |
title_sort | inclusion of n-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978999/ https://www.ncbi.nlm.nih.gov/pubmed/24246100 http://dx.doi.org/10.1186/ar4383 |
work_keys_str_mv | AT thakkarvivek theinclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT stevenswendy theinclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT priordavid theinclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT youssefpeter theinclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT liewdanny theinclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT gabbayeli theinclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT roddyjanet theinclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT walkerjenniferg theinclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT zochlingjane theinclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT sahharjoanne theinclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT nashpeter theinclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT lestersusan theinclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT rischmuellermaureen theinclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT proudmansusannam theinclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT nikpourmandana theinclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT thakkarvivek inclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT stevenswendy inclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT priordavid inclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT youssefpeter inclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT liewdanny inclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT gabbayeli inclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT roddyjanet inclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT walkerjenniferg inclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT zochlingjane inclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT sahharjoanne inclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT nashpeter inclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT lestersusan inclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT rischmuellermaureen inclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT proudmansusannam inclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy AT nikpourmandana inclusionofnterminalprobrainnatriureticpeptideinasensitivescreeningstrategyforsystemicsclerosisrelatedpulmonaryarterialhypertensionacohortstudy |